Contents Link Navigation Link
ABOUT US

Targeting, Attacking, and Eradicating Cancers®

Company History

Targeting, Attacking, and Eradicating Cancers®

2017
may.Collaboration with Regeneron Pharmaceuticals on PD-1 and Pexa-Vec combination therapy
markmarkmark
2016
Dec.SillaJen is listed on KOSDAQ market in South Korea.

Jan.SillaJen announces first patient randomized in multinational Phase 3 trial for Pexa-Vec in Advanced Liver Cancer.
markmarkmark
2015
Oct.SillaJen is selected as the major developer for the Government project of “Global State-of-the-art technology development for biomedical products".
markmark
2015
Apr.SillaJen reached agreement with the US FDA on a Special Protocol Assessment (SPA) for multinational Phase 3 clinical trial of Pexa-Vec in Advanced Liver Cancer.
mark
2014
Mar.SillaJen acquires Jennerex, Inc., the global leader in oncolytic immunotherapeutics.
mark
2013
May.US FDA designated Pexa-Vec as an orphan drug.
mark
2011
Jun.Jennerex initiated Pexa-Vec Phase 2b clinical trial (HEP018) for Liver Cancer.
markmark
2009
Nov.European Medicines Agency (EMA) designated Pexa-Vec as an orphan drug for Live Cancer.
markmarkmark
2008
Aug.Jennerex initiated Pexa-Vec Phase 2a clinical trial (HEP007).
mark
2007
Aug.Jennerex completed Pexa-Vec Phase 1 clinical trial (HEP001).
markmark
2006
Mar.SillaJen, Inc. was established.
markmarkmark
2003
Nov.Jennerex, Inc. (San Francisco, USA) was established.
mark